Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

White House targets blockbusters in Medicare’s price negotiation strategy

By Brian Buntz | September 1, 2023

White House

Photo by Tabrez Syed on Unsplash

The Biden-Harris Administration has nominated 10 drugs for price negotiations directly with pharmaceutical giants after capping monthly insulin costs at $35.

Americans have historically paid more for prescription drugs than most other major economies. In a fact sheet, the White House highlighted that seniors paid $3.4 billion in out-of-pocket costs for these drugs just last year. Biden, like Trump before him, aim to bring prices more in line with those of other advanced nations.

This move is not isolated. The Biden Administration has implemented other cost-saving measures, such as reining in the cost of insulin and making some vaccines free for Medicare beneficiaries.

All of the 10 drugs on the list were blockbusters. Eight of the 10 were among the bestselling drugs of 2022. The remaining two are insulin formulations from Novo Nordisk: Fiasp and NovoLog.

The list of nominated drugs includes:

1. Eliquis (apixaban)

  • 2022 Sales: $18,269,000,000
  • Medicare Part D Costs (June 2022-May 2023): $16,482,621,000
  • Common Indications: Prevention and treatment of blood clots

2. Stelara (ustekinumab)

  • 2022 Sales: $9,723,000,000
  • Medicare Part D Costs (June 2022-May 2023): $2,638,929,000
  • Common Indications: Plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease

3. Imbruvica (ibrutinib)

  • 2022 Sales: $8,352,000,000
  • Medicare Part D Costs (June 2022-May 2023): $2,663,560,000
  • Common Indications: Chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion, Waldenström’s macroglobulinemia

4. Xarelto (rivaroxaban)

  • 2022 Sales: $7,460,849,000
  • Medicare Part D Costs (June 2022-May 2023): $6,031,393,000
  • Common Indications: Reducing risk of stroke in nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, DVT prophylaxis following knee or hip replacement surgery

5. Januvia/Janumet (sitagliptin)

  • 2022 Sales: $4,513,000,000
  • Medicare Part D Costs (June 2022-May 2023): $4,087,081,000
  • Common Indications: Type 2 diabetes

6. Farxiga (dapagliflozin)

  • 2022 Sales: $4,386,000,000
  • Medicare Part D Costs (June 2022-May 2023): $3,268,329,000
  • Common Indications: Type 2 diabetes mellitus, heart failure

7. Enbrel (etanercept)

  • 2022 Sales: $4,117,000,000
  • Medicare Part D Costs (June 2022-May 2023): $2,791,105,000
  • Common Indications: Plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis

8. Entresto (sacubitril/valsartan)

  • 2022 Sales: $4,644,000,000
  • Medicare Part D Costs (June 2022-May 2023): $2,884,877,000
  • Common Indications: Chronic heart failure and reduced ejection fraction

9 and 10. Fiasp and NovoLog–branded products

  • 2022 Sales: Unavailable
  • Medicare Part D Costs (June 2022-May 2023): $2,576,586,000
  • Common Indications: Diabetes

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE